LAWRENCEVILLE, N.J.,
July 14, 2014 /PRNewswire/
-- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug
development company, announced today that the Company will ring the
NASDAQ Stock Market closing bell on Wednesday, July 16, 2014 in Times Square,
New York, NY.
President and CEO Michael H.
Tardugno and members of the Celsion and EGEN management
teams will participate in the closing bell ringing ceremony from
3:45 pm to 4:00 pm ET. A live
webcast will be available at
https://new.livestream.com/nasdaq/live.
"Celsion has achieved significant milestones during the first
half of 2014, including our recent strategic acquisition of EGEN
and the launch of a pivotal, double-blind, placebo-controlled,
global Phase III trial (the OPTIMA Study) for our lead development
candidate, ThermoDox® in primary liver cancer," said Michael H. Tardugno, Celsion's President and
Chief Executive Officer. "Ringing the closing bell at NASDAQ
commemorates this progress, which establishes Celsion as a fully
integrated oncology development company with multiple product
candidates and technology platforms, and a robust development
effort with ongoing or planned Phase III, II and I studies."
As previously announced, in June
2014, the Company completed the acquisition of EGEN, a
privately-held biopharmaceutical company focused on the development
of nucleic acid-based therapeutics for the treatment of cancer and
other difficult to treat diseases. The acquisition includes EGEN's
Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its
therapeutic platform technologies, TheraPlas™ for delivery of DNA
and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell
Enabled Expression and Secretion of RNA. With this acquisition,
Celsion is now focused on the leading-edge of cancer treatment,
with assets in directed chemotherapies, immunotherapies and DNA- or
RNA-based therapies.
About Celsion Corporation
Celsion is fully-integrated oncology company focused on
developing a portfolio of innovative cancer treatments, including
directed chemotherapies, immunotherapies and RNA- or DNA-based
therapies. The Company's lead program is ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, currently in
Phase III development for the treatment of primary liver
cancer. The pipeline also includes EGEN-001, a DNA-based
immunotherapy for the localized treatment of ovarian and brain
cancers. Celsion has three platform technologies for the
development of novel nucleic acid-based immunotherapies and other
anti-cancer DNA or RNA therapies, including TheraPlasTM,
TheraSilenceTM and RASTTM. For more
information on Celsion, visit our website:
http://www.celsion.com.
Celsion wishes to inform readers that forward-looking
statements in this release are made pursuant to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of
1995. Readers are cautioned that such forward-looking
statements, including, without limitation, statements about the
acquisition and the combined company as well as clinical and
pre-clinical programs, involve risks and uncertainties. These risks
and uncertainties include, without limitation, difficulties and
operational and financial risks associated with integrating Celsion
and EGEN after completion of the acquisition; unforeseen changes in
the course of research and development activities and in clinical
trials; the significant expense, time, and risk of failure of
conducting clinical trials; the need for Celsion to evaluate its
future development plans; termination of the Technology Development
Contract or collaboration between Celsion and Hisun at any time;
possible changes in cost and timing of development and testing,
capital structure, financial condition, working capital needs and
other financial items; possible acquisitions or licenses of other
technologies, assets or businesses or the possible failure to make
such acquisitions or licenses; possible actions by customers,
suppliers, competitors, regulatory authorities; and other risks
detailed from time to time in the Celsion's periodic reports filed
with the Securities and Exchange Commission, including its Form
10-Q filed on May 8, 2014. Celsion
assumes no obligation to update or supplement forward-looking
statements that become untrue because of subsequent events, new
information or otherwise.
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
SOURCE Celsion Corporation